(PSTV) Plus Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PSTV) Plus Therapeutics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Plus Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the company’s product, price, place, and promotion strategy and shows how its oncology offerings are positioned and distributed; this page includes a real preview/sample of the analysis so you can evaluate style and substance. Purchase the full version to get the complete, ready-to-use report.
Product
R-186 NL
R-186 NL, Plus Therapeutics’ patented Rhenium-186 NanoLiposome, is the company’s core product and lead clinical-stage asset. It uses the 186Re isotope, with a 3.72-day half-life, to deliver radiation directly into hard-to-treat CNS tumors.
The program sits at the center of Plus Therapeutics’ pipeline and is advancing in Phase 1/2 studies, so its product edge depends on local delivery, dose control, and safety.
Recurrent glioblastoma
R-186 NL targets recurrent glioblastoma, a fast-moving adult brain cancer with a median overall survival of about 15 months after diagnosis and a 5-year survival rate near 5%. Plus Therapeutics, Inc. is aiming at a high-need market where many patients relapse after surgery, radiation, and temozolomide, leaving few options. That unmet need supports the product's pricing and positioning.
Leptomeningeal metastases
Plus Therapeutics, Inc. targets leptomeningeal metastases, a rare cancer spread to the membranes around the brain and spinal cord. This severe CNS condition is seen in roughly 5% of solid-tumor patients and often carries survival of only weeks to a few months without effective treatment. That leaves a large unmet need for better, more precise therapies.
Pediatric brain cancers
Plus Therapeutics targets pediatric brain cancers, a rare but high-need area with about 4,000 U.S. children and teens diagnosed with brain and other CNS tumors each year. Its radiotherapy approach is aimed at difficult pediatric CNS tumors, where options remain limited and survival for diffuse midline glioma is often under 1 year.
- Rare, high-unmet-need segment
- Targets tough pediatric CNS tumors
- Can widen clinical reach
NanoTx glioblastoma license
Plus Therapeutics, Inc.’s NanoTx license adds an external glioblastoma asset to its pipeline and broadens its oncology mix beyond R-186 NL. Glioblastoma remains a high-unmet-need market, with median survival near 15 months for newly diagnosed patients, so this license targets a large clinical gap.
- External asset, not internal-only R&D
- Supports broader oncology strategy
- Targets a hard-to-treat brain cancer
Plus Therapeutics Bets on Precision Radiation for Rare Brain Cancers
Plus Therapeutics, Inc.’s product mix is led by R-186 NL, a patented Rhenium-186 NanoLiposome that delivers radiation locally to hard-to-treat CNS tumors. It targets recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers, where survival is often months and treatment options are limited. The product’s edge is precise dosing, local delivery, and a broad rare-disease fit.
| Product | Focus | Key fact |
|---|---|---|
| R-186 NL | CNS tumors | 186Re half-life: 3.72 days |
| NanoTx license | Glioblastoma | Expands oncology pipeline |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of Plus Therapeutics, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses Plus Therapeutics’ 4Ps into a quick, clear view that helps teams spot gaps and align faster.
Reference Sources
Cites primary industry reports, FDA filings, and peer‑reviewed studies so investors can quickly verify Plus Therapeutics’ market, pricing, and competitive assumptions.
Place
Austin, Texas headquarters
Plus Therapeutics is headquartered in Austin, Texas, and that 1 site serves as its central operating base. Core corporate, development, and strategic functions are managed there, so decisions move through one hub. Austin also gives the Company access to Texas's dense life-science talent pool and lower operating costs than many coastal markets.
Clinical-site distribution
Plus Therapeutics, Inc. has no retail “place” network; access runs through investigator-led, hospital-based oncology trial sites. In 2025, its pipeline stayed clinical-stage, so distribution was concentrated in specialized cancer centers instead of pharmacies or wholesalers. That fit the model for investigational cancer drugs, where enrollment and dosing happen at a limited site network.
Specialty neuro-oncology centers
Specialty neuro-oncology centers are the right place for Plus Therapeutics, Inc. because CNS cancers need advanced imaging, radiation planning, and neurosurgical expertise. With U.S. brain and other CNS cancers causing about 25,000 new cases a year, hospital-based access matters more than broad pharmacy reach. These centers also speed trial enrollment and specialist adoption.
Regulatory pathway access
Plus Therapeutics, Inc. can only reach patients through FDA and other regulatory pathways until approval, so access stays tied to clinical sites, not open retail distribution. In 2025, this kept the therapy in development settings and limited where patients could receive it. One checkpoint can decide the whole launch map.
- FDA status drives access
- Clinical sites only before approval
- Approval expands patient reach
Future hospital commercialization
If approved, Plus Therapeutics, Inc.'s CNS radiotherapy would likely be given in hospitals or specialty infusion centers, where controlled handling and neurologic monitoring are standard. That keeps commercialization in a narrow, high-acuity channel tied to specialist prescribers, imaging, and treatment planning.
Plus Therapeutics, Inc. reported $1.5 million in 2024 revenue and a $22.4 million net loss, while cash and equivalents were $8.2 million at year-end 2024, underscoring the need for a tightly targeted launch.
- Hospital-only use limits the sales channel
- Specialist sites drive adoption
- Controlled administration supports safety
Hospital-Only Access Defines Plus Therapeutics’ Distribution
Plus Therapeutics, Inc. uses a hospital-led "place" model: access runs through specialist oncology centers, not retail channels. In 2025, its clinical-stage pipeline kept distribution tied to investigator sites and FDA pathways, so reach stayed narrow. If approved, delivery would likely stay in hospitals or specialty infusion centers.
| Place factor | Data |
|---|---|
| HQ | Austin, Texas |
| Access channel | Hospital trial sites |
| 2025 stage | Clinical-stage |
What You See Is What You Get
Plus Therapeutics, Inc. Reference Sources
The preview shown here is the actual Plus Therapeutics, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—complete, editable, and ready for immediate use with no surprises.
Promotion
Clinical trial disclosures
Plus Therapeutics uses clinical trial disclosures to show pipeline progress, which is the main message for a development-stage biotech. Updates on trial starts, patient enrollment, and data readouts help investors and partners track execution, especially across its CNS cancer programs. For a company still burning cash and seeking repeat funding, these disclosures are central to credibility and deal interest.
Press releases
Plus Therapeutics, Inc. uses press releases as its main promotion tool, which fits a small biotech with limited ad spend. In 2025-2026, it used public announcements to share development, licensing, and FDA/regulatory updates across its pipeline, helping drive visibility with investors, partners, and clinicians.
This channel matters because one news item can move a micro-cap story fast, and Plus Therapeutics relies on frequent milestone updates instead of broad consumer marketing.
SEC filings
Plus Therapeutics, Inc. promotes through SEC filings, using 10-K, 10-Q, and 8-K reports to keep investors updated on revenue, cash, risks, and pipeline progress. These filings give the market a direct view of program status, including trial milestones and financing needs, so the company’s story is tied to verified disclosures, not ads.
Scientific and medical outreach
Plus Therapeutics, Inc. leans on scientific outreach to build trust with oncologists, hospitals, and researchers. In its latest 2025 reporting, the Company kept its focus on clinical data readouts and peer-facing presentations, a key signal for adoption in radiopharma where evidence, not ads, drives buy-in. This helps turn trial milestones into clinical credibility.
- Peer-reviewed data builds clinician trust
- Conference talks support adoption
- Clinical evidence drives promotion
Partner and licensing news
Partner and licensing news is a direct promotion tool for Plus Therapeutics, Inc. The NanoTx licensing agreement works as third-party validation, showing outside groups see value in the oncology pipeline. Each deal also widens market awareness and can pull more attention to the Company Name’s CNS cancer programs.
- Signals outside validation
- Boosts oncology pipeline visibility
- Supports brand trust in licensing
Plus Therapeutics' 3 disclosure channels can move the stock fast
Plus Therapeutics, Inc. promotes through 3 core disclosure channels: press releases, SEC filings, and scientific presentations. In 2025-2026, those updates centered on trial starts, enrollment, licensing, and FDA progress, which matters for a micro-cap biotech with no broad consumer marketing. One data readout can shift visibility fast.
| Promotion channel | 2025-2026 use |
|---|---|
| Press releases | Trial and deal updates |
| SEC filings | 10-K, 10-Q, 8-K |
| Scientific outreach | Conference data |
Price
No approved product price
Plus Therapeutics, Inc. has no approved commercial list price for R-186 NL as of July 2026 because the therapy is still clinical-stage. The company has not begun broad sales, so pricing has not been set in the market. Any price will only be announced after regulatory clearance and market approval.
Clinical-stage funding
Plus Therapeutics still has $0 product sales, so its “price” is really the cost of funding trials and manufacturing. The company depends on equity raises, grants, and other financing to keep clinical programs moving. In 2025, cash runway and dilution matter more than unit pricing, because capital is the product’s real input cost.
Undisclosed license economics
Plus Therapeutics, Inc. has not publicly detailed the NanoTx license economics, so the upfront fee, milestone payments, and royalty rate stay undisclosed. In biotech licensing, those three terms usually determine how much revenue the licensor can capture over time, from 0 upfront to double-digit milestone packages in some deals. Without the contract terms, the price side of this 4P remains hard to model.
Future reimbursement dependence
If Plus Therapeutics, Inc. wins approval, realized price will hinge on payer coverage, prior auth, and coding, not just list price. For hospital-administered oncology drugs, Medicare often pays under Part B at ASP + 6% for physician use, while hospital outpatient payment can vary by status and mix. That matters most for high-cost specialty therapies, where weak reimbursement can cut uptake fast.
- Payer coverage drives net price.
- Codes affect hospital uptake.
Specialty oncology value model
Plus Therapeutics, Inc. fits a specialty oncology value model, not mass-market pricing. U.S. brain and other CNS tumors were estimated at 25,400 new cases and 18,760 deaths in 2025, so pricing can stay premium when clinical benefit is clear and use stays in expert cancer centers.
- Expert-center use supports premium pricing
- High unmet need can justify value-based rates
- Strong outcomes matter more than volume
- CNS cancer market is small, severe, and specialized
Plus Therapeutics R-186 NL Has No List Price Yet
Plus Therapeutics, Inc. has no commercial list price for R-186 NL in 2026, because the therapy is still clinical-stage and has $0 product sales. For now, price is driven by trial funding, dilution, and undisclosed license terms, not market demand. If approved, payer coverage and coding will shape net price more than the headline tag.
| Price driver | Latest 2025/2026 data |
|---|---|
| Commercial list price | $0; no approval yet |
| U.S. CNS cancer need | 25,400 cases; 18,760 deaths in 2025 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.